GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » ROIC %

AXSM (Axsome Therapeutics) ROIC % : -165.25% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Axsome Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2024 was -165.25%.

As of today (2024-12-14), Axsome Therapeutics's WACC % is 8.17%. Axsome Therapeutics's ROIC % is -220.82% (calculated using TTM income statement data). Axsome Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Axsome Therapeutics ROIC % Historical Data

The historical data trend for Axsome Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics ROIC % Chart

Axsome Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,360.90 -1,796.70 -2,054.82 -322.73 -170.39

Axsome Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -224.84 -197.08 -247.92 -275.19 -165.25

Competitive Comparison of Axsome Therapeutics's ROIC %

For the Biotechnology subindustry, Axsome Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's ROIC % falls into.



Axsome Therapeutics ROIC % Calculation

Axsome Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-182.907 * ( 1 - -0.4% )/( (103.443 + 112.104)/ 2 )
=-183.638628/107.7735
=-170.39 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=331.476 - 78.952 - ( 200.842 - max(0, 96.561 - 245.642+200.842))
=103.443

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=588.236 - 110.723 - ( 386.193 - max(0, 138.854 - 504.263+386.193))
=112.104

Axsome Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2024 is calculated as:

ROIC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-184.932 * ( 1 - 0% )/( (111.067 + 112.75)/ 2 )
=-184.932/111.9085
=-165.25 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=548.226 - 160.702 - ( 315.657 - max(0, 186.57 - 463.027+315.657))
=111.067

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=561.458 - 165.782 - ( 327.341 - max(0, 196.187 - 479.113+327.341))
=112.75

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Axsome Therapeutics  (NAS:AXSM) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Axsome Therapeutics's WACC % is 8.17%. Axsome Therapeutics's ROIC % is -220.82% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Axsome Therapeutics ROIC % Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics Business Description

Traded in Other Exchanges
Address
One World Trade Center, 22nd Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Executives
Mark E Saad director C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Mark L. Jacobson officer: Chief Operating Officer 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
Mark Coleman director 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Roger Jeffs director
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Hunter R. Murdock officer: General Counsel 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Nick Pizzie officer: Chief Financial Officer 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Herriot Tabuteau director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
David C Marek officer: Chief Commercial Officer C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski officer: Chief Financial Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye officer: Chief Medical Officer 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance officer: Vice President, Finance 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc 10 percent owner 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111

Axsome Therapeutics Headlines